Compare Neurocrine Biosciences Inc (NBIX) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Paycom Software Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Paycom Software Inc trades at $144.05 (market cap $6.98B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.5× Paycom Software Inc's market cap, and Paycom Software Inc pays a 1% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PAYC | |
|---|---|---|
Market Cap | $17.40B | $6.98B |
Sector | Health | Technology |
52-Week High | $180.55 | $238.80 |
52-Week Low | $123.10 | $113.59 |
Enterprise Value | $16.49B | $7.59B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Paycom Software (PAYC) trades at $144.22, down 2.51% today, with a bullish technical signal and strong fundamentals including 22.44% net margin and 37.15% ROE. Recent earnings beat expectations in Q1 2026, and the company launched a new Asset Management tool. Cash flow from operations grew to $679M in 2025, though net cash flow declined from 2024's peak.
Outlook remains positive with analyst consensus near current price ($144.60 target) and 47% buy ratings. Risks include high P/B of 8.6 and reliance on HR software demand. The stock offers value with a reasonable P/E of 17.33 but faces execution risks in maintaining growth against competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
